Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow LSTA
Lisata Therapeutics, Inc. (LSTA) EV/Sales
As of 16 October 2026, Lisata Therapeutics, Inc. (LSTA) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −2.3× (December 2022) to 7.0× (February 2015); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | — |
| FY2024 | −0.1× | — |
| FY2015 | 2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 0.2× | (23.92%) |
| Jun 2025 | 0.3× | (70.40%) |
| Mar 2016 | 1.0× | (52.98%) |
| Dec 2015 | 2.1× | (36.42%) |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −5.9× |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. | 0.1× |
| BLRX BioLineRx Ltd. compare | 1.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)